Comparative Pharmacology
Head-to-head clinical analysis: INDIUM IN 111 PENTETREOTIDE KIT versus PHOSPHOTOPE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDIUM IN 111 PENTETREOTIDE KIT versus PHOSPHOTOPE.
INDIUM IN-111 PENTETREOTIDE KIT vs PHOSPHOTOPE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Indium In-111 pentetreotide binds to somatostatin receptors, particularly subtypes 2 and 5, allowing scintigraphic localization of primary and metastatic neuroendocrine tumors bearing these receptors.
Unknown; proposed to normalize phosphate metabolism and inhibit ectopic calcification by binding to calcium and phosphate.
111 MBq (3 mCi) indium In-111 pentetreotide administered intravenously over 1 minute; single dose for planar and SPECT imaging.
10-20 mcg/kg intravenous bolus over 1-2 minutes, may repeat every 10-20 minutes as needed for hemodynamic support. Maximum total dose: 1 mg.
None Documented
None Documented
Terminal half-life approximately 24 hours (range 22-26 hours), allowing imaging up to 24-48 hours post-injection
Terminal elimination half-life: 4-6 hours in patients with normal renal function; prolonged to 12-24 hours in moderate renal impairment (CrCl <30 mL/min) and >24 hours in dialysis-dependent patients.
Renal: 80-90% unchanged within 24 hours; Fecal: 5-10%
Renal: 70-80% as unchanged drug; fecal: 15-20% as metabolites; biliary: <5%.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical